ODM-201: A new-generation androgen receptor inhibitor in castration-resistant prostate cancer

Karim Fizazi, Laurence Albiges, Yohann Loriot, Christophe Massard

    Research output: Contribution to journalArticlepeer-review

    67 Citations (Scopus)

    Abstract

    Androgen deprivation therapy is the standard of care for patients with advanced hormone-sensitive prostate cancer. Despite an initial response, most patients progress to castration-resistant prostate cancer (CRPC). The realization that CRPC remains driven by androgen receptor (AR) signaling has formed the basis for a new generation of agents targeting the AR axis. Two of these agents, abiraterone acetate and enzalutamide, have been shown to prolong overall survival in patients with CRPC. Several other AR inhibitors are currently in development for the treatment of CRPC. The present article reviews ODM-201, a new-generation AR inhibitor with a unique molecular structure, in the treatment of CRPC. The design of an ongoing Phase III trial (ARAMIS) of ODM-201 in men with non-metastatic CRPC is also discussed, at a disease stage for which there is currently no approved treatment.

    Original languageEnglish
    Pages (from-to)1007-1017
    Number of pages11
    JournalExpert Review of Anticancer Therapy
    Volume15
    Issue number9
    DOIs
    Publication statusPublished - 2 Sept 2015

    Keywords

    • ODM-201
    • androgen receptor inhibitors
    • castration resistant
    • efficacy
    • metastatic
    • non-metastatic
    • pharmacodynamics
    • pharmacokinetics
    • prostate cancer
    • tolerability

    Cite this